Lumito receives patent approval in India

Lumito AB (publ) (“Lumito” or the “Company”) today announces that the Company has been granted a patent in India relating to its technology for tissue analysis using upconverting nanoparticles. The patent has previously been granted in Europe and the United States and further strengthens Lumito’s international intellectual property protection. The granted patent protects the technology […]

Two Swedish research customers place orders for Lumito’s SCIZYS Erbium Kit

Lumito AB (publ) (“Lumito” or the “Company”) today announces that two Swedish research customers have placed orders for the Company’s SCIZYS Erbium kit. The orders include the use of the Company’s Scan-as-a-Service offering and strengthen the Company’s position within the research segment. Both customers require the high sensitivity enabled by Lumito’s technology. The first order […]

Changes to the Nomination Committee ahead of Lumito’s Annual General Meeting 2026

Lumito AB (publ) (“Lumito” or the “Company”) today announces that the composition of the Nomination Committee ahead of the Annual General Meeting 2026 has changed as a result of changes in the Company’s ownership structure. The composition of the Nomination Committee ahead of the Annual General Meeting 2026, based on ownership statistics from Euroclear Sweden […]

Analyst Group initiates coverage of Lumito

Lumito AB (publ) (”Lumito” or the “Company”) today announces that Analyst Group has initiated equity research coverage of Lumito, commissioned by the Company. The coverage includes equity research with quarterly updates as well as analyst comments on financial reports and press releases. Analyst Group’s full equity research report on the Company is expected to be […]

Lumito receives order from Swedish research unit

Lumito AB (publ) (“Lumito” or the “Company”) today announces that the Company has received an order for a SCIZYS Erbium kit from a research unit in Sweden. The customer will utilise the Company’s Scan-as-a-Service offering. The Company has received an order at an initial value of 10-20 kSEK from an organisation that has experienced limitations […]

Lumito publishes investor letter – 2025 in review and the road ahead

Lumito AB (publ) (“Lumito” or “the Company”) today announces the publication of its latest investor letter, which summarises the development in 2025 and also presents the Company’s priorities for 2026. “During 2025, we took several important steps in market introduction and commercialisation. We have methodically built insights, relationships, structures and processes, all of which are […]

The Board of Directors of Lumito proposes a reversed share split

Lumito AB’s (publ) (“Lumito” or “the Company”) Board of Directors proposes that an extraordinary general meeting resolves on a reverse share split, whereby five hundred (500) existing shares are consolidated into one (1) new share. If the extraordinary general meeting resolves in accordance with the proposal, the total number of shares in the Company will […]

Lumito’s technology enables quantification of low abundant cells

Lumito AB (publ) (“Lumito” or the “Company”) today announces new results from its collaboration with Truly Labs AB (“Truly Labs”), demonstrating that Lumito’s tissue analysis technology enables significantly improved detection of low abundant, “rare”, cells compared to conventional staining methods. The results were presented at the Pharma Outsourcing conference, organised by Life Science Sweden, on […]

Lumito strengthens its international presence and participates in Digital Pathology & AI Congress Europe

Lumito AB (publ) (“Lumito” or the “Company”) is this week participating in one of Europe’s leading conferences for digital pathology, image analysis, and AI-driven technologies, the Digital Pathology & AI Congress: Europe in London. The conference gathers representatives from the pharmaceutical industry, CROs, hospital laboratories, academia, and technology companies to discuss developments within digital and […]